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Abbreviations
BP blood pressure
CHD coronary heart disease
CO2 carbon dioxide
COPD chronic obstructive pulmonary disease
CPX cardiopulmonary exercise testing
CRF cardiorespiratory fitness
CV cardiovascular
ECG electrocardiogram
EIB exercise-induced bronchospasm
EOV exercise oscillatory ventilation
ET exercise testing
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HF heart failure
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HR heart rate
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ILD interstitial lung disease
LVH left ventricular hypertrophy
MVV maximal voluntary ventilation
O2 oxygen
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PEF peak expiratory flow
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PH pulmonary hypertension
Q cardiac output
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SpO2 pulse oximetry
US United States
VE minute ventilation
VCO2 carbon dioxide production
VO2 oxygen consumption
VT ventilatory threshold
Introduction
From an evidence-based perspective, cardiopulmonary exercise
testing (CPX) is a well-supported assessment technique in both
the United States (US) and Europe. The combination of standard
exercise testing (ET) [i.e. progressive exercise provocation in asso-
ciation with serial electrocardiograms (ECGs), haemodynamics,
oxygen saturation, and subjective symptoms] and measurement
of ventilatory gas exchange amounts to a superior method to:
(i) accurately quantify cardiorespiratory fitness (CRF), (ii) delineate
the physiologic system(s) underlying exercise responses, which can
be applied as a means to identify the exercise-limiting pathophysio-
logical mechanism(s) and/or performance differences, and (iii) for-
mulate function-based prognostic stratification. Cardiopulmonary
ET certainly carries an additional cost as well as competency
requirements and is not an essential component of evaluation in
all patient populations. However, there are several conditions of
confirmed, suspected, or unknown aetiology where the data
gained from this form of ET is highly valuable in terms of clinical
decision making.1
Several CPX statements have been published by well-respected
organizations in both the US and Europe.1 –5 Despite these prom-
inent reports and the plethora of pertinent medical literature
which they feature, underutilization of CPX persists. This discrep-
ancy is at least partly attributable to the fact that the currently
available CPX consensus statements are inherently complex and
fail to convey succinct, clinically centred strategies to utilize CPX
indices effectively. Likewise, current CPX software packages gener-
ate an overwhelming abundance of data, which to most clinicians
are incomprehensible and abstract.
Ironically, in contrast to the protracted scientific statements and
dense CPX data outputs, the list of CPX variables that have proven
clinical application is concise and uncomplicated. Therefore, the
goal of this writing group is to present an approach of CPX in a
way that assists in making meaningful decisions regarding a patient’s
care. Experts from the European Association of Cardiovascular
Prevention and Rehabilitation and American Heart Association
have joined in this effort to distil easy-to-follow guidance on
CPX interpretation based on current scientific evidence. This
document also provides a series of forms that are designed to high-
light the utility of CPX in clinical decision-making. Not only will this
improve patient management, it will also catalyze uniform and un-
ambiguous data interpretation across laboratories on an inter-
national level.
The primary target audience of this position paper is clinicians
who have limited orientation with CPX but whose caregiving
would be enhanced by familiarity and application of this assess-
ment. The ultimate goal is to increase awareness of the value of
CPX and to increase the number of healthcare professionals
who are able to perform clinically meaningful CPX interpretation.
Moreover, this document will hopefully lead to an increase in ap-
propriate patient referrals to CPX with enhanced efficiencies in
patient management. For more detailed information on CPX, in-
cluding procedures for patient preparation, equipment calibration,
and conducting the test, readers are encouraged to review other
publications that address these and other topics in great detail.1– 5
What is cardiopulmonary exercise
testing?
Despite advances in technologies related to diagnostic testing and
the popularity of imaging techniques, the assessment of exercise
responses provides critical enhancement of the evaluation of
patients with or suspected of having cardiovascular (CV) or pul-
monary disease.6 The measurement of CRF from ET has many clin-
ical applications, including diagnosis, evaluation of therapy, risk
stratification, and to guide physical activity. While exercise toler-
ance is commonly estimated from treadmill or bicycle cycle ergom-
eter work rate, CPX is a specialized subtype of ET that provides a
more accurate and objective measure of CRF. CPX relies on the
measurement of ventilatory gases during exercise, i.e. a non-
invasive procedure that involves the acquisition of expired ventila-
tion and concentrations of oxygen (O2) and carbon dioxide (CO2)
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during progressive exercise. Admittedly, there are potential
‘patient difficulties’ associated with CPX (trepidation with the
testing itself, mouthpiece/nose clip/mask difficulties, perception of
limits in ‘air’ availability, etc.). However, when added to standard
ET, the direct non-invasive measurement of ventilation and
expired gases permits the most accurate and reproducible quanti-
fication of CRF, a grading of the aetiology and severity of impair-
ment, and an objective assessment of the response to an
intervention.7,8 Moreover, over the last two decades, a particularly
large volume of research has been directed toward the utility of
CPX as a prognostic tool; these studies have established CPX as
a scientifically sound and therefore clinically valuable method for
accurately estimating prognosis in various disease states.1,9,10 As
will be described in this document, studies performed on the clin-
ical applications of CPX have had an important influence on the
functional assessment of patients with confirmed/suspected CV
and pulmonary disease as well as those with certain confirmed/sus-
pected musculoskeletal disorders.
Although still underutilized, CPX has gained popularity not only
due to the recognition of its clear value in the functional assess-
ment of patients with CV, pulmonary, and musculoskeletal
disease/disorders, but also because of technological advances
(e.g. rapid response analysers and computer-assisted data process-
ing) which have made this modality easier to use. Once largely
under the domain of the physiologist or specialized centre, CPX
currently has the potential to be used for a wide spectrum of clin-
ical applications. The basic CPX responses, O2 consumption VO2
( )
,
minute ventilation (VE), and CO2 production VCO2
( )
are now easily
obtainable in the time-down spreadsheet format from most
systems, providing a platform for straightforward data processing
and interpretation. While standard ET has long been considered
the gatekeeper to more expensive and invasive procedures (e.g.
angiography, bypass surgery, transplantation, other medical man-
agement decisions), gas exchange measurements during exercise
have been demonstrated to enhance the decision-making
process. CPX responses have been demonstrated to be valuable
in supplementing other clinical information to optimize risk strati-
fication for cardiac transplantation listing, medical device therapy
(e.g. implantable cardioverter-defibrillator and cardiac resynchroni-
zation therapy), consideration for lung resection or lung trans-
plantation, and for a variety of pre-surgical evaluations.1,7,9 – 13
Because markers of ventilatory efficiency have emerged as particu-
larly powerful prognostic markers, risk stratification paradigms that
include these indices have also been proposed in recent years.1,13
Defining key cardiopulmonary
exercise testing variables14–23
The volume of data automatically generated by the software
packages of CPX systems can be somewhat daunting to clinicians
who do not have extensive experience with this form of ET. More-
over, the clinical significance of many of these variables, numerical-
ly and/or graphically depicted, has not been thoroughly vetted
through original research. In contrast, the list of variables most per-
tinent in current clinical practice, and which are well substantiated
by original research, is relatively concise. Key CPX variables,
derived from both ventilatory expired gas analysis data and stand-
ard ET monitoring, are listed in Table 1. The intent of this table is to
identify the key CPX variables and to provide only succinct
descriptions or their significance and normal values/responses;
more detailed accounts are provided elsewhere and the reader
is encouraged to review these documents for additional
details.1– 4,24 Of particular note, aerobic capacity is defined as
peak VO2 as opposed to maximal VO2 in this document as the
former designation is most often used in patient populations
with suspected/confirmed pathophysiological processes. All of
the variables listed in Table 1 are included in the one-page, univer-
sal CPX reporting form (see Appendix 1). While some of these
variables warrant assessment in all patients undergoing CPX,
such as peak VO2 and the peak respiratory exchange ratio (RER),
others, such as the VE/VCO2 slope and exercise oscillatory ventila-
tion (EOV), are condition specific. A more refined identification of
condition-specific CPX variables is described in subsequent sec-
tions and their respective appendices. The writing group hopes
that this approach improves the ease by which the most pertinent
data are identified and utilized by clinicians performing and inter-
preting CPX. Moreover, the majority of these variables are auto-
matically included in reporting forms generated by current CPX
system software packages.
Depending on system configuration, standard ET measures, such
as haemodynamics and heart rate (HR), will either be reported
alongside ventilatory expired gas analysis data or reported separ-
ately. In either situation, the majority of essential data is readily
obtained. O2 pulse and (change in VO2/change in Watt
(DVO2/DW) plots are often generated by customary CPX software
systems. If this is not the case, the plots can be easily generated
using the exercise data reported in time-down spreadsheet
format. Examples of normal and abnormal O2 pulse and
DVO2/DW plots are illustrated in Figure 1.
While VE data are graphically depicted, determination of EOV
must be performed manually at this time. Given the importance
of determining EOV in heart failure (HF), the writing group
anticipates that the presence or absence of this abnormality,
according to universally adopted criteria, will be automatically
quantified by future CPX system software packages. The most
frequently used criteria currently to define EOV are listed in
Table 1.16 There is initial evidence to indicate that this set of
EOV criteria provides more robust prognostic insight compared
with other methods.25 For present clinical applications, the
writing group recommends rest and exercise VE data be graph-
ically depicted using 10-s averaged samples. This averaging inter-
val allows for the removal of breath-by-breath signal noise while
preventing excessive data smoothing and loss of the physiologic-
al phenomena that is brought about by averaging over longer
intervals (i.e. data used for graphic illustration listed as ≥30 s
averaging). A normal ventilatory pattern is contrasted to EOV
in Figure 2.
Lastly, when the additional assessment of non-invasive cardiac
output (Q) is performed (e.g. CPX for suspected mitochondrial
myopathy), the DQ/DVO2 slope can be easily determined from
the ET data in time-down spreadsheet format.
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Table 1 Identification and defining normal responses for key cardiopulmonary exercise testing variables
CPX variable Description/significance Normal value/response
Peak VO2
(mL O2 † kg21 †min21)
† Highest O2 uptake obtained during exercise
† Commonly designated as ‘peak’ value in patient
populations described in this document
† Expressed as a 10–60 s averaged value depending on
the ET protocol (i.e. shorter averaging interval for
protocols with shorter stages and longer averaging
interval for protocols with longer stages)1
† Response influenced by central (CV and/or
pulmonary) and peripheral (skeletal muscle) function
† Broadly reflects disease severity in a number of patient
populations including HF, HCM, PAH secondary PH,
COPD, ILD
† Universal prognostic marker
† Wide range influenced by age and sex: 80–15
mL O2 † kg21 †min21 in young elite athlete and
apparently healthy 80-year-old female, respectively;11
normal age-related decline related to decrease in central
and peripheral performance across the lifespan; normal
sex-related differences largely influenced by difference in
maximal cardiac output
† Reporting peak VO2 as a per cent-predicted value using
equations provided in Table 2 recommended to account
for age and sex differences.
† Per cent-predicted values should be ≥100%
VO2 at VT
(mL O2 † kg21 †min21)
† Submaximal VO2 where there is a dislinear rise in VE
and VCO2
† Generally associated with anaerobic threshold
† Represents upper limit of ET workloads that can be
sustained for a prolonged period
† Valuable in setting intensity for exercise prescription in
a highly individualized manner
† ≈ 50–65% of peak VO2 21
† Influenced by genetic predisposition and chronic aerobic
training
Peak RER † Defined as the VCO2/VO2 ratio
† Expressed as a 10–60 s averaged value depending on
exercise protocol (i.e. shorter averaging interval for
protocols with shorter stages and longer averaging
interval for protocols with longer stages)
† As exercise progresses to higher intensities, VCO2
outpaces VO2 , increasing the ratio
† Currently is the best non-invasive indicator of exercise
effort
† Peak value ≥1.10 widely accepted as excellent exercise
effort1
VE/VCO2 slope † Relationship between VE, plotted on the y-axis, and
VCO2 plotted on the x-axis; both variables in L min
21
† Most commonly calculated using all ET data7
† Represents matching of ventilation and perfusion
within the pulmonary system
† Broadly reflects disease severity as well as prognosis in
a number of patient populations including HF, HCM,
PAH/secondary PH, COPD, ILD
,30 considered normal with slight increase with advanced
age possible
EOV † No universal definition currently available
† Most commonly defined as an oscillatory pattern at
rest that persists for ≥60% of the exercise test at an
amplitude of ≥15% of the average resting value1,16
† Recommend using 10 s averaged VE data for plotting
† Reflects advanced disease severity and poor prognosis
in patients with HF
This is not a normal ventilatory response to exercise under
any circumstances (see Figure 2)
PETCO2 (mmHg) at rest and
during exercise
† Also represents matching of ventilation and perfusion
within the pulmonary system and cardiac function
† Broadly reflects disease severity in a number of patient
populations including HF, HCM, PAH/secondary PH,
COPD, ILD
† Rest: 36–42 mmHg
† Increases between 3 and 8 mmHg by VT
† Decrease following VT secondary to increased ventilation
response
VE/VO2 at peak exercise † Expressed as a 10–60 s averaged value depending on
the exercise protocol (i.e. shorter averaging interval
for protocols with shorter stages and longer averaging
interval for protocols with longer stages)
† Reflects ventilatory cost of O2 uptake at peak ET
† Has diagnostic utility in patients with suspected
mitochondrial myopathy
† ≤ 40
† 50 ¼ upper limit of normal response22
Continued
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Table 1 Continued
CPX variable Description/significance Normal value/response
DQ/DVO2 slope † Relationship between Q, plotted on the y-axis, and VO2
plotted on the x-axis; both variables in L min21
† Additional equipment needed to measure Q; through
foreign gas rebreathing technique1
† Reflects the relationship between O2 delivery and
utilization in exercising skeletal muscle
† Has diagnostic utility in patients with suspected
mitochondrial myopathy if anaemia is ruled out
≈5
VE/MVV † Ratio between VE at maximal exercise and MVV
obtained at rest; both variables in L min21
† Although prediction equations are available
(FEV1 × 4023), MVV should be directly measured
† Has diagnostic utility in determining if unexplained
exertional dyspnoea is related to a pulmonary
mechanism
≤0.80
FEV1 (L †min21) and PEF
(L †min21)
† Components of pulmonary function testing battery
† Predicted values automatically generated by CPX unit
software packages; influenced by age, sex and body
habitus
† Has diagnostic utility in determining if unexplained
exertional dyspnoea is related to a pulmonary
mechanism, particularly exercise-induced
bronchospasm
† When relevant, should be assessed prior to and
following CPX for comparative purposes
,15% reduction from pre to post CPX for both variables
O2 pulse trajectory
(mL O2 † beat21)
† O2 pulse defined as the ratio between VO2
(mL O2 †min21) and HR (b.p.m.)
† Non-invasively reflects stroke volume response to
exercise
† Has diagnostic utility in patients with suspected
myocardial ischemia (i.e. exercise-induced left
ventricular dysfunction)
Continual linear rise throughout exercise with possible
plateau approaching maximal exertion (see Figure 1)
DVO2/DW trajectory
(mL †min21 †W21)
† Plot of the relationship between VO2 (y-axis in mL
min21) and workload (x-axis in W)
† Lower extremity ergometer should be used as
exercise mode when assessed
† Has diagnostic utility in patients with suspected
myocardial ischaemia (i.e. exercise-induced left
ventricular dysfunction)
† Continual linear rise throughout ET (see Figure 1)
† Average slope, calculated with all exercise data, is
10 mL †min21 †W21
Exercise HR (b.p.m.) † In patients not prescribed a beta-blocking agent;
provides insight into chronotropic competence and
cardiac response to exercise
† Peak HR should not be used as the primary gauge of
subject effort given its wide variability19,20
† Increase 10 beats per 3.5 mL O2 † kg21 †min21
increase in VO2 , achieve at least 85% of age-predicted
maximal HR with good effort
HRR at 1 min (beats) † Difference between maximal exercise HR and HR
1 min into recovery
† Provides insight into speed of parasympathetic
reactivation
.12 beats
Exercise BP (mmHg) Provides insight into CV response to exercise and left
ventricular afterload
† SBP increase 10 mmHg per 3.5 mL O2 † kg21 †min21
increase in VO2
† Upper range of normal maximal SBP is 210 mmHg for
males and 190 mmHg for females
† DBP remains the same or slightly decreases
Continued
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Figure 2 Examples of normal ventilatory pattern (A) and exer-
cise oscillatory ventilation pattern (B). VE, minute ventilation.
Figure 1 Normal (dashed line) and abnormal (solid line)
example of oxygen pulse and DVO2/DW plots. VO2, oxygen con-
sumption; W, watts; O2, oxygen.
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Table 1 Continued
CPX variable Description/significance Normal value/response
SpO2 (%) † Non-invasive estimate of arterial haemoglobin
saturation
† Has diagnostic utility in determining if unexplained
exertional dyspnoea is related to a pulmonary
mechanism
† Desaturation common in patients with COPD, ILD,
PAH/secondary PH as disease severity advances
† ≥ 95% at rest and throughout exercise
† Should not decrease .5% (absolute value)
ECG † Insight into stability of cardiac rhythm
† Identifies baseline abnormalities and exercise-induced
ischaemia
† Minimal waveform changes
† No significant deviation from normal sinus rhythm
Subjective symptoms † Used to determine subjects perception of symptoms
limiting exercise
† Rating of perceived exertion (i.e. Borg scale)15 as well
as dyspnoea and angina (using symptom specific
scales)17 should be quantified using separate scales
with unique verbal anchors
† Unusual dyspnoea as primary reason for test
termination (i.e. 4/4: severely difficult, patient cannot
continue)17 shown to indicate increased adverse event
risk in patients assessed for myocardial ischemia14 and
HF18
† Limiting factor muscular fatigue with no significant
dyspnoea or angina
CPX, cardiopulmonary exercise testing; VO2 , oxygen consumption; ET, exercise testing; VT, ventilatory threshold; VE, minute ventilation; VCO2 , carbon dioxide production; RER,
respiratory exchange ratio; EOV, exercise oscillatory ventilation; PETCO2, partial pressure of end-tidal carbon dioxide; HF, heart failure; HCM, hypertrophic cardiomyopathy; PAH,
pulmonary arterial hypertension; PH, pulmonary hypertension; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; Q, cardiac output; MVV; maximal
voluntary ventilation; PEF, peak expiratory flow; FEV1, forced expiratory volume in 1 s; O2, oxygen; W, watt; HR, heart rate; HRR, heart rate recovery; BP, blood pressure; SBP,
systolic blood pressure; DBP, diastolic blood pressure; SpO2, saturation of peripheral oxygen; ECG, electrocardiogram.
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Universal cardiopulmonary
exercise testing reporting form
The ability to collect all relevant CPX data in a concise and orga-
nized manner is essential for meaningful data interpretation and
clinical utilization. The universal CPX reporting form included as
Appendix 1 provides clinicians with the ability to collect relevant
ET data that may subsequently be used for interpretation accord-
ing to a patient’s specific condition/test indication. It should be
noted that some of the variables in the CPX reporting form will
be collected irrespective of the reason for ET. This includes peak
VO2 , per cent-predicted peak VO2 , VO2 at ventilatory threshold
(VT), peak RER, HR, blood pressure (BP), ECG, and subjective
symptom data. To calculate per cent-predicted peak VO2 , the
writing group proposes using the equations put forth by Wasser-
man and Hansen,26,27 which are listed in Table 2. These equations
account for several influencing factors including body habitus,
mode of exercise, and sex. The aforementioned variables are rele-
vant to all patients undergoing CPX because of their ability to uni-
versally reflect prognosis, maximal and submaximal functional
capacity, exercise effort, and exertional physiology.28,29 The collec-
tion of other CPX variables included in the universal CPX report-
ing form are dictated by test indication and described in
subsequent sections and appendices.
Unique condition-related
cardiopulmonary exercise testing
variables according to test
indication
There are several suspected/confirmed conditions where per-
formance of a CPX would provide clinically valuable information
on diagnosis, prognosis, and/or therapeutic efficacy. However,
the volume of scientific evidence supporting the value of CPX
is heterogeneous across the conditions identified in subsequent
sections. While the clinical use of CPX is firmly established in
patients with systolic HF and unexplained exertional dyspnoea,
additional research, to varying degrees, is needed to further
bolster support for CPX in the other patient populations identi-
fied in this document. This is not to suggest that a clinical justifi-
cation for CPX cannot be made for each of the conditions listed
below. Moreover, the unique condition-related CPX variables
proposed for analysis are based on a sound physiological ration-
ale, expert consensus, and current scientific evidence. The
writing group feels that, based on expert opinion and currently
available evidence, CPX provides valuable clinical information in
all of the conditions listed in subsequent sections. Each of the fol-
lowing sections is accompanied by a condition-specific evaluation
chart (see Appendices 2–8). These charts include key CPX vari-
ables for each test indication in a colour-coded format.
Responses in the green zone indicate a normal response for a
given variable, while responses in the yellow and red zones indi-
cate progressively greater abnormalities. An interpretation, based
on CPX performance for key variables, is included at the end of
each chart. The intent of these condition-specific charts is to
greatly simplify CPX data interpretation, thereby improving clin-
ical utility.
Systolic heart failure
The majority of research assessing the clinical application of CPX
has been performed within the systolic HF population. Beginning
in the 1980s with the landmark work by Weber et al.,30 followed
in 1991 with the classic investigation by Mancini et al.,31 a wealth
of literature has been put forth that convincingly demonstrates
the ability of key CPX variables to predict adverse events and
gauge disease severity.1,7,32,33 Peak VO2 and the VE/VCO2 slope
are currently the most studied CPX variables in patients with
Table 2 Predicted peak oxygen consumption equations
Wasserman/
Hansen
equationsa
Sedentary male
Step 1: Calculate
Cycle factor ¼ 50.72 – 0.372(age)
Predicted weight ¼ 0.79 (height) – 60.7
Step 2: Classify weight
Measured weight¼ predicted weight
Step 3: Select equation
Measured weight < Predicted weight
Peak VO2 (mL †min21) ¼ [(Predicted weight + Actual
weight)/2] × cycle factor
Measured weight5 Predicted weight
Peak VO2 (mL †min21) ¼ Measured weight × cycle factor
Measured weight > Predicted weight
Peak VO2 (mL †min21) ¼ (Predicted weight × cycle
factor) + 6 × (Measured weight – predicted weight)
Step 4: Mode of exercise consideration
If treadmill used for test
Multiply predicted VO2 from step 3 × 1.11
Sedentary Female
Step 1: Calculate
Cycle factor ¼ 22.78 – 0.17 (age)
Predicted weight ¼ 0.65 (height) – 42.8
Step 2: Classify weight
Measured weight ¼ predicted weight
Step 3: Select equation
Measured weight < Predicted weight
Peak VO2 (mL †min21) ¼ [(Predicted weight + Actual weight
+86)/2] × cycle factor
Measured weight5 Predicted weight
Peak VO2 (mL †min21) ¼ (Measured weight + 43) × cycle
factor
Measured weight > Predicted weight
Peak VO2 (mL †min21) ¼ (Predicted weight + 43) × cycle
factor + 6 × (Measured weight – predicted weight)
Step 4: Mode of exercise consideration
If treadmill used for test
Multiply predicted VO2 from step 3 × 1.11
VO2 , oxygen consumption.
aHeight in cm and weight in kg.
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systolic HF and both demonstrate strong, independent prognostic
value. While there is evidence to indicate the VE/VCO2 slope is a
stronger univariate predictive marker compared with peak VO2 ,
there is substantial evidence to indicate that a multivariate ap-
proach improves prognostic accuracy.7 Under current medical
management strategies, a VE/VCO2 slope ≥45 and a peak VO2
,10.0 mL O2 † kg21 †min21 are indicative of a particularly
poor prognosis over the 4-year period following CPX.34 Other
CPX variables have emerged in recent years that appear to
further refine prognostic resolution. Specifically, EOV and the
partial pressure of end-tidal CO2 (PETCO2) during rest and exer-
cise have both demonstrated strong prognostic value in patients
with systolic HF.16,35– 37 Given these variables are readily available,
their inclusion for prognostic assessment purposes is recom-
mended. Lastly, there is some evidence to indicate the assessment
of per cent-predicted peak VO2 may provide prognostic informa-
tion,38– 40 although it is not clear if such information supersedes/
compliments the prognostic strength of measured peak VO2 .
Current evidence indicates that a per cent-predicted peak VO2
value falling below 50% indicates a poor prognosis in patients
with HF.38 Research assessing the clinical value of per
cent-predicted peak VO2 assessment in patients with HF should
continue. However, given the disparity in the volume of support-
ing evidence for the prognostic value of measured peak VO2 vs.
per cent-predicted peak VO2 , we currently recommend the
actual peak VO2 value being considered in this patient population
to gauge disease severity and prognosis. The prognostic and diag-
nostic stratification chart for patients with systolic HF is provided
in Appendix 2. The peak VO2 , the VE/VCO2 slope, presence/
absence of EOV, and rest/exercise PETCO2 should all be assessed.
As values for these variables progress to the red zone, disease se-
verity worsens and the likelihood of major adverse events (i.e.
death, HF decompensation to the refractory stage) becomes in-
creasingly likely. The risk for softer endpoints, such as hospitaliza-
tion due to HF, is also likely to increase as variables progress to
the red zone. With respect to transplant candidacy, the peak VO2
and VE/VCO2 slope values in the red zone should be considered
primary criteria for eligibility. Numerous investigations have
demonstrated the aforementioned CPX variables respond favour-
ably to pharmacological (i.e. sildenafil, angiotensin receptor block-
ade, angiotensin-converting enzyme inhibition), surgical (i.e.
cardiac resynchronization therapy, left ventricular assist device im-
plantation, and heart transplantation), and lifestyle (i.e. exercise
training) interventions appropriate for patients with systolic
HF.7,41 –43 Therefore, when CPX abnormalities are detected a
review of the patient’s clinical management strategy is recom-
mended in order to determine whether titration of current inter-
ventions or the implementation of new interventions is
warranted. In addition, standard ET variables should be included
in the assessment as they may provide further information on clin-
ical stability and prognosis. An abnormal haemodynamic and/or
ECG response, as well as an abnormally low HR recovery
(HRR) at 1 min post-ET and report of unusual dyspnoea (i.e. 4/
4: severely difficult, patient cannot continue)17 as the primary sub-
jective symptom eliciting test termination, provide further evi-
dence of poor prognosis and greater disease severity.18,29,44,45
Heart failure with preserved ejection
fraction and congenital heart disease
Several studies are now available that support the use of CPX for
gauging the level of diastolic dysfunction and assessing prognosis in
patients with HF-preserved ejection fraction (HF-PEF).46– 48
VE/VCO2 slope and EOV both appear to hold the prognostic
value in patients with HF-PEF at a level comparable with that
found in patients with systolic HF. Moreover, several investigations
similarly support the prognostic importance of CPX in the con-
genital heart disease population.49– 51 Even so, additional research
is needed in these patient populations to further elucidate the clin-
ical value of CPX. At this time, the writing group recommends that
the same reporting chart should be used for patients with systolic
HF, HF-PEF, and congenital heart disease (see Appendix 2).
Hypertrophic cardiomyopathy
Cardiopulmonary ET has promising utility in regard to the assess-
ment of patients with suspected/confirmed HCM. Ventilatory
expired gas analysis during ET can be used to demarcate functional
limitations, with diagnostic and prognostic implications. While the
2002 American College of Cardiology/American Heart Association
ET guidelines52 cite HCM as a relative contraindication to ET, many
investigators have subsequently highlighted that the technique is
safe.53–55 Not only can peak VO2 be used as criterion by which
to guide HCM management, but it can also serve to distinguish
left ventricular hypertrophy (LVH) associated with HCM from
LVH stemming from relatively more innocuous aetiologies. Ath-
letes may, for example, have physiological hypertrophy induced
by physical activity. In this context, CPX can be applied to differen-
tiate physiological hypertrophy from LVH in HCM simply on the
basis of ET performance. While athletes achieve peak VO2 that typ-
ically exceed the predicted values, only 1.5% of HCM patients have
peak VO2 exceeding the predicted values,
56 providing a convenient
way to help recognize HCM in young adults who may have LVH
but who are asymptomatic and have not been diagnosed with
the condition. Measures of ventilatory efficiency, specifically the
VE/VCO2 slope and PETCO2, may also be valuable in patients
with HCM as abnormalities in these variables have been associated
with increased pulmonary pressures as a consequence of advanced
LVH-induced diastolic dysfunction.57 Moreover, recent evidence
indicates that aerobic capacity and ventilatory efficiency are prog-
nostic markers in minimally symptomatic patients with obstructive
HCM.58 As a provocative exercise stimulus, CPX also provides an
important assessment of ECG and haemodynamics. A blunted
(≤20 mmHg increase in systolic BP) or hypotensive (exercise sys-
tolic BP, resting values) exercise BP response is also common
and indicates an increased risk of sudden death.59,60 Moreover,
prognostic implications are even worse when abnormal haemo-
dynamic responses are coupled to a low peak VO2 .
61 While
exercise-induced serious ventricular arrhythmias are comparatively
rare, they may also be associated with high prognostic risks in
some patients.62 The prognostic and diagnostic stratification
chart for patients with confirmed or suspected HCM is provided
in Appendix 3. Given the range of peak VO2 values is likely to be
wide in this patient population, a per cent-predicted value, which
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has recently demonstrated prognostic value in this population,58
should be included in the assessment. A progressive decline in
per cent-predicted values, from green to red, is indicative of wor-
sening disease severity and prognosis. Abnormalities in standard
haemodynamic (i.e. systolic blood pressure) and ECG (i.e. onset
of ventricular arrhythmias) variables, progressing to the red
zone, are further indication of worsening disease severity and
increased risk for adverse events. As values for the VE/VCO2
slope and PETCO2 progress from green to red, the likelihood of
secondary pulmonary hypertension (PH), induced by HCM, is
increased.
Unexplained exertional dyspnoea
Cardiopulmonary exercise testing possesses the unique ability to
comprehensively assess the independent and integrated exertional
responses of the CV and pulmonary systems. Moreover, the major-
ity of current CPX systems have the capability to perform pulmon-
ary function testing. Therefore, in patients presenting with
unexplained exertional dyspnoea, CPX is considered an important
assessment to determine the mechanism of exercise intoler-
ance.1,52 When CPX is utilized for this indication, a primary goal
should be to reproduce the patient’s exertional symptoms in
order to optimally detect any coinciding physiological abnormal-
ities. The diagnostic stratification chart for patients with unex-
plained exertional dyspnoea is provided in Appendix 4. The
VE/VCO2 slope, per cent-predicted peak VO2 , PETCO2, and the
peak exercise VE/maximal voluntary ventilation (MVV) ratio are
primary CPX variables for this assessment. Maximal voluntary ven-
tilation should be directly measured prior to exercise as opposed
to estimated using forced expiratory volume in 1 s (FEV1). More-
over, pulmonary function tests should be performed prior to
and following CPX to determine FEV1 and peak expiratory flow
(PEF).63–67 Following CPX, FEV1, and PEF should be measured at
1, 3, 5, 7, 10, 15, and 20 min, as responses for these variables typ-
ically worsen several minutes into recovery when exercise induced
bronchospasm (EIB) is present.67 In addition to the standard
haemodynamic and ECG monitoring procedures, pulse oximetry
(SpO2) should also be assessed at rest, throughout ET, and into re-
covery. Given the range of peak VO2 values is likely to be wide in
this patient population, a per cent-predicted value should be
included in the assessment. A progressive decline in per
cent-predicted values, from green to red, indicates that the physio-
logical mechanism resulting in exertional dyspnoea is having a
greater impact on functional capacity. Abnormalities in the
VE/VCO2 slope and PETCO2, particularly progressing to the red
zone, indicate ventilation–perfusion abnormalities induced by pul-
monary vasculopathy68,69 as a potential mechanism for exertional
symptoms. Patients with ventilation–perfusion abnormalities may
also present with a reduced SpO2, and, in such instances, this
finding portends advanced pathophysiology. Isolated abnormalities
(i.e. red zone) in VE/MVV, FEV1, and PEF are indicative of a pul-
monary mechanism for the patient’s unexplained exertional dys-
pnoea. For FEV1 and PEF responses in the red zone, EIB should
be suspected and a bronchodilator trial may be warranted.
While both FEV1 and PEF have been recommended for the
assessment of EIB, FEV1 is frequently assessed in isolation.
65,66
Thus, a decrease in FEV1 .15% post exercise, irrespective of
the PEF response, is sufficient to suspect EIB.67 Detection of
haemodynamic and/or ECG abnormalities that coincide with
reproduced exertional dyspnoea are indicative of a CV mechanism
for the patient’s unexplained symptoms. Unique to CPX for this
indication, a hypertensive response to exercise that coincides
with exertional dyspnoea and exercise intolerance may be an
early indicator of HF-PEF.70,71
Suspected or confirmed pulmonary
arterial hypertension or secondary
pulmonary hypertension
Although not currently a standard clinical indication for CPX, the
body of evidence supporting the use of this form of ET in patients
with suspected or confirmed PAH and secondary PH is growing at
an impressive rate.68,69,72– 82 A key value of CPX in detecting po-
tential pulmonary vasculopathy, or gauging disease severity once a
diagnosis has been made, is the ability of this exercise approach to
non-invasively quantify ventilation–perfusion abnormalities. Specif-
ically, abnormalities in the VE/VCO2 slope and PETCO2 are strongly
suggestive of pulmonary vasculopathy whose aetiology is either
PAH or secondary PH as a consequence of other primary condi-
tions such as HF, HCM, chronic obstructive pulmonary disease
(COPD), interstitial lung disease (ILD), or systemic connective
tissue diseases. Moreover, there is emerging evidence to suggest
key CPX variables portend the prognostic value in patients with
PAH. The prognostic and diagnostic stratification chart for
patients with suspected or confirmed PAH or secondary PH is
provided in Appendix 5. Peak VO2 , the VE/VCO2 slope, and
PETCO2 are primary CPX variables in patients with suspected
or confirmed PAH or secondary PH. Patients suffering from pul-
monary vasculopathy, regardless of the mechanism, typically
present with significantly compromised aerobic capacity. Thus,
reporting peak VO2 as an actual value, using the Weber classifica-
tion system,30 is warranted. In those patients without a confirmed
diagnosis, the likelihood of pulmonary vasculopathy increases as
values for the VE/VCO2 slope and PETCO2 progress from green
to red. In patients with a confirmed diagnosis of PAH/secondary
PH, progressively worsening abnormalities of the aforementioned
ventilatory efficiency variables as well as aerobic capacity are indi-
cative of increasing disease severity. Moreover, worsening
responses in these primary CPX variables are indicative of
increased risk for adverse events. With respect to mode of
testing, there is evidence to suggest ventilatory efficiency abnor-
malities are more pronounced during treadmill ET compared
with cycle ergometry.83 Therefore, treadmill CPX may be
optimal when assessing patients with suspected or confirmed pul-
monary vasculopathy. In addition, patients with advanced PAH/
secondary PH often present with an abnormal reduction in
SpO2. Lastly, abnormal haemodynamic and/or ECG responses
further compound concerns over increasing disease severity and
prognosis in these patients.
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Confirmed chronic obstructive
pulmonary disease or interstitial lung
disease
The literature supporting the use of CPX in patients with
confirmed COPD or ILD is beginning to increase, producing com-
pelling results in support of this form of ET for these patient popu-
lations. Several investigations have demonstrated that peak VO2 is
predictive of adverse events in patients with COPD84,85 and
ILD.86,87 Like patients with HF, a peak VO2 ,10 mL O2 † kg21 †
min21 portends a particularly poor prognosis. The prognostic
ability of peak VO2 in patients with pulmonary disease has led the
American College of Chest Physicians to recommend that CPX
be used pre-surgically in lung resection candidates to assess post-
surgical risk.88 Initial evidence also indicates the VE/VCO2 slope is a
significant post-surgical prognostic marker in patients with COPD
undergoing lung resection.89 Additionally, the ability of CPX to
gauge ventilatory efficiency is valuable in screening for secondary
PH in patients with COPD and ILD.90,91 As the VE/VCO2 slope pro-
gressively increases and PETCO2 progressively decreases above and
below their normal values, respectively, the presence of secondary
PH becomes more likely. The prognostic and diagnostic stratifica-
tion chart for patients with COPD and ILD is provided in Appen-
dix 6. Peak VO2 , the VE/VCO2 slope, and PETCO2 are primary CPX
variables for both COPD and ILD patients. As values for these vari-
ables progress to the red zone, there is an increased risk for
adverse events and greater likelihood of secondary PH. Addition-
ally, standard exercise variables progressing to the red zone com-
pound the concern for poor prognosis in these patients.
Suspected myocardial ischaemia
Standard incremental ET procedures are a well-accepted and
valuable clinical assessment tool in patients at high risk for myocar-
dial ischaemia.6,52,92 The use of ventilatory expired gas analysis for
patients undergoing ET for suspected myocardial ischaemia is not
commonplace in the clinical setting at this time. In recent years,
however, several investigations have demonstrated the potential
diagnostic utility of CPX in this setting.93,94 Recent studies have
found that the real-time change in the O2 pulse and DVO2/DW
trajectories are most valuable when using CPX to assess
exercise-induced myocardial ischaemia. Under normal physiologic-
al conditions, both of these relationships progressively rise during
maximal ET. However, left-ventricular dysfunction induced by
myocardial ischaemia causes both the O2 pulse and DVO2/DW tra-
jectories to prematurely flatten or decline (see Figure 1). In a land-
mark study, Belardinelli et al.95 performed CPX in 202 patients
with a confirmed diagnosis of coronary heart disease (CHD),
using 2-day stress/rest-gated SPECT myocardial scintigraphy as
the gold standard for myocardial ischaemia. Using logistic regres-
sion, flattening of the O2 pulse and DVO2/DWR trajectories were
independent predictors of exercise-induced myocardial ischaemia.
The sensitivity and specificity for O2 pulse + DVO2/DW flattening
as criteria for exercise-induced myocardial ischaemia were 87 and
74%, respectively. Comparatively, ECG criteria for
exercise-induced myocardial ischaemia, defined as the onset of
1.0 mm horizontal ST-segment depression in at least two adjacent
leads, produced a sensitivity and specificity of 46 and 66%,
respectively. Of particular note, the addition of O2 pulse and
DVO2/DW trajectory assessments helped to rule out ischaemia
in a significant portion of individuals for whom the ECG was
falsely positive. As a technical note, the majority of investigations
validating the clinical applications of CPX for patients with sus-
pected myocardial ischaemia to this point, including the landmark
investigation by Belardinelli et al.,95 used a lower extremity
bicycle ergometry as the mode of testing. Thus, additional research
should be conducted to determine whether the diagnostic utility of
CPX for myocardial ischaemia is present when a treadmill is the
testing mode. The diagnostic stratification chart for patients with
suspected myocardial ischaemia is provided in Appendix 7. Assess-
ment of the O2 pulse and DVO2/DW trajectories are primary CPX
variables. As values for these variables progress to the red zone,
the likelihood of exercise-induced myocardial ischaemia increases.
Given that the range of peak VO2 values is likely to be wide in
patients undergoing CPX for this indication, a per cent-predicted
value should be included in the assessment. A progressive
decline in per cent-predicted values, from green to red, is indicative
of poorer aerobic fitness and possibly increased coronary artery
disease severity. Previous research has demonstrated lower per
cent-predicted aerobic fitness values to be indicative of poor prog-
nosis.96 As with all ET procedures, standard haemodynamic and
ECG variables should be assessed in patients with suspected myo-
cardial ischaemia. Abnormalities in these measures progressing to
the red zone further increase the likelihood of exercise-induced
myocardial ischaemia and provide prognostic insight.29 Lastly, evi-
dence suggests patients with suspected myocardial ischaemia who
report unusual dyspnoea (i.e. 4/4: severely difficult, patient cannot
continue)17 as the primary reason for exercise limitations have a
poorer prognosis compared with those whose primary limiting
symptom is lower extremity fatigue or angina.14 While research
demonstrating the value of CPX in this area is promising, additional
investigations are needed to further substantiate CPX for this
purpose, particularly in cohorts with suspected myocardial ischae-
mia and no prior workup bias.
Suspected mitochondrial myopathy
A number of genetic abnormalities exist which can lead to dimin-
ished CRF and a host of other exertional abnormalities uniquely
captured by CPX.22,97 The degree of impairment in peak VO2
appears to correlate to the severity of genetic mutation.22,98 More-
over, patients with mitochondrial myopathies have an elevated
VE/VO2 ratio at peak exercise, as the ventilatory cost of VO2 dra-
matically rises due to aerobic inefficiency by affected skeletal
muscle. The ability to non-invasively quantify Q during CPX in an
accurate manner is now possible through foreign gas rebreathing
methods.1 Using this technique, the relationship between
Q (y-axis) and VO2 (x-axis) during ET are plotted, generating a
slope value. In normal circumstances, where O2 utilization and de-
livery are well matched, the DQ/DVO2 slope is 5 L min
21. In sub-
jects with mitochondrial myopathies, this slope is much higher as
oxygen delivery far exceeds the capacity for utilization.22 The
diagnostic stratification chart for patients with suspected mito-
chondrial myopathy is provided in Appendix 8. The assessment
of the DQ/DVO2 slope and peak VE/VO2 are primary CPX variables.
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As values for these variables progress to the red zone, the likeli-
hood of a mitochondrial myopathy increases. Moreover, the
degree of abnormality in the DQ/DVO2 slope and peak VE/VO2 re-
sponse is indicative of the degree of mitochondrial mutation load.
Given the range of peak VO2 values is likely to be wide in patients
undergoing CPX for this indication, a per cent-predicted value
should be included in the assessment. A progressive decline in
per cent-predicted values, from green to red, when coinciding
with an abnormal DQ/DVO2 slope and peak VE/VCO2 , is likewise in-
dicative of an increasingly higher mitochondrial mutation load.
When these variables are abnormal, a muscle biopsy would be war-
ranted to obtain a definitive diagnosis. Additionally, standard
haemodynamic and ECG variables should be assessed in patients
with suspected mitochondrial myopathy, as abnormalities in these
measures are universally indicative of CV abnormalities and
increased adverse event risk.29
Directions for future research
The current statement provides recommendations for CPX data
interpretation based on currently available scientific evidence and
expert consensus. However, there are other CPX variables that
may emerge as clinically important measures in a number of the
patient populations described herein. Examples of CPX variables
demonstrating the potential value are the oxygen uptake efficiency
slope,99–101 circulatory power102 and VO2 onset
103,104 and recov-
ery105 kinetics. Moreover, additional research is needed to
further increase support for the use of CPX in certain patient
populations as previously mentioned. Additional investigations
into the value of CPX in females also seem warranted across all
patient populations that would benefit from this form of ET.
Lastly, future investigations are needed to determine whether
other patient populations would benefit from CPX as a compo-
nent of their clinical assessment. For example, there is some
initial data to indicate CPX may provide valuable information in
patients with atrial fibrillation, a condition associated with ventila-
tory and functional abnormalities.106,107 This writing group
encourages continued research into the clinical utility of CPX
across all patient populations where a viable case can be made
for this form of ET, addressing specific questions in need of
further analysis. Future investigations in this area will lead to add-
itional refinement of CPX utilization and data interpretation as
well as improve the clinical value of this assessment technique.
Conclusions
Cardiopulmonary exercise testing is well recognized as the gold
standard aerobic ET assessment. The use of CPX is well estab-
lished in the clinical setting for both patients with systolic HF,
undergoing a pre-transplant assessment, and individuals with un-
explained exertional dyspnea.6,52 The evidence supporting the
use of CPX in patients with confirmed or suspected PAH and
secondary PH is also rapidly expanding and a strong case for
the application of this ET assessment in this population can
now be made. There is also emerging evidence to demonstrate
CPX elicits clinically valuable information in a number of other
patient populations, which are described in this document. Irre-
spective of the reason for the ET assessment, the utility of CPX
currently suffers from an inability to easily interpret the most
useful information in a way that is evidence based and specific
to test indication. The present document attempts to rectify
this issue by coalescing expert opinion and current scientific evi-
dence and creating easily interpretable CPX charts that are indi-
cation specific. It is the hope of the writing group that this
document will expand the appropriate use of CPX by simplifying
data interpretation, thereby increasing the clinical value of the
data obtained.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Appendix 1: Universal CPX reporting form (complete all boxes that apply for given ET indication)
Exercise modality: [ ] Treadmill [ ] Lower extremity ergometer
Protocol:
Peak VO2 (mL O2†kg21†min21) Per cent-predicted peak VO2 (%)a VE/VCO2 slope
VO2 at VT (mL O2†kg21†min21) Peak RER EOV [ ] Yes [ ] No
PETCO2 (mmHg) VE/VO2 at peak ET DQ/DVO2
b
Resting:
Increase during ET:
VE/MVVc: PEF (L/min): Pre-ET Post-ET
O2 pulse trajectory
d
[ ] Continual rise throughout ET [ ] Early and sustained plateau [ ] Decline
DVO2/DW trajectory
d
[ ] Continual rise throughout ET [ ] Early and sustained plateau [ ] Decline
Resting HR (b.p.m.) Resting BP (mmHg) Resting pulse oximetry (%)
Peak HR (b.p.m.) Peak BP (mmHg) Peak pulse oximetry (%)
Percent of age-predicted maximal HRe Maximal workload
HRR at 1 min (beats) [ ] Treadmill speed/grade:
[ ] Cycler ergometer Watts:
ECG criteria ECG description
[ ] No arrhythmias/Ectopy/ST segment changes
[ ] Arrhythmias/Ectopy/ST segment changes: not exercise limiting
[ ] Arrhythmias/Ectopy/ST segment changes: exercise limiting
Subjective symptoms (check box for primary termination criteria)
RPE [ ] Angina [ ] Dyspnoea [ ]
Additional notes
CPX, cardiopulmonary exercise testing; ET, exercise testing; VO2, oxygen consumption; VT, ventilator threshold; RER, respiratory exchange ratio; VE/VCO2, minute ventilation/
carbon dioxide production; EOV, exercise oscillatory ventilation; PETCO2, partial pressure of end-tidal carbon dioxide production; VE/VO2, minute ventilation/oxygen
consumption; VE/MVV, peak minute ventilation/maximal voluntary ventilation; DQ/DVO2, change in cardiac output/change in oxygen consumption; PEF, peak expiratory flow; O2,
oxygen; DVO2/DW, change in oxygen consumption/change in Watts; HR, heart rate; BP, blood pressure; HRR, heart rate recovery; ECG, electrocardiogram; RPE, rating of
perceived exertion
aUse equations proposed by Wasserman.
bRequires additional equipment of assess Q response to exercise through non-invasive rebreathing technique.
cDirectly measure MVV at baseline.
dRequires O2 pulse and DVO2/DW plot from initiation to end of ET. If these variables required for assessment, electronically braked cycle ergometer should be used for testing.
eUse equation: (peak HR/220-age) * 100.
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Appendix 2: Prognostic and diagnostic stratification for patients with HF
Primary CPX variables
VE/VCO2 slope Peak VO2
a EOV PETCO2
Ventilatory class I Weber class A
Not present
Resting PETCO2
VE/VCO2 slope ,30.0 Peak VO2 .20.0 mL O2†kg21†min21 ≥33.0 mmHg
Ventilatory class II Weber class B 3–8 mmHg increase during ET
VE/VCO2 slope 30.0–35.9 Peak VO2 ¼ 16.0–20.0 mL O2†kg21†min21
Ventilatory class III Weber class C
Present
Resting PETCO2
VE/VCO2 slope 36.0–44.9 Peak VO2 ¼ 10.0–15.9 mL O2†kg21†min21 ,33.0 mmHg
Ventilatory class IV Weber class D ,3 mmHg increase during exercise
VE/VCO2 slope ≥45.0 Peak VO2 ,10.0 mL O2†kg21†min21
Standard ET variables
Haemodynamics ECG HRR
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST segment changes
during ET and/or in recovery
.12 beats at 1 min recovery
Flat systolic BP response during exercise Altered rhythm, ectopic foci, and or ST segment changes during ET
and/or in recovery: did not lead to test termination
≤12 beats at 1 min recovery
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment changes during ET
and/or in recovery: led to test termination
Patient reason for test termination
Lower extremity muscle fatigue Angina Dyspnoea
Interpretation
† All variables in green: excellent prognosis in next 1–4 years (≥90% event free)
– Maintain medical management and retest in 4 years.
† Greater number of CPX and standard ET variables in red/yellow/orange indicative of progressively worse prognosis.
– All CPX variables in red: risk for major adverse event extremely high in next 1–4 years (.50%).
† Greater number of CPX and standard ET variables in red/yellow/orange indicative of increasing HF disease severity.
– All CPX variables in red: expect significantly diminished cardiac output, elevated neurohormones, higher potential for secondary PH.
† Greater number of CPX and standard ET variables in red/yellow/orange warrants strong consideration of more aggressive medical management and
surgical options.
VE/VCO2, minute ventilation/carbon dioxide production; VO2, oxygen consumption; EOV, exercise oscillatory ventilation; PETCO2, partial pressure of end-tidal carbon dioxide; BP,
blood pressure; CPX, cardiopulmonary exercise test; ECG, electrocardiogram; ET, exercise test; HRR, heart rate recovery; RER, respiratory exchange ratio.
aPeak VO2 valid if peak RER is at least 1.00 or test terminated secondary to abnormal haemodynamic or ECG exercise response.
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Appendix 3: Prognostic and diagnostic stratification for patients with confirmed or suspected HCM
Primary CPX variables
VE/VCO2 slope Per cent-predicted peak VO2
a PETCO2 apex during ET
b
Ventilatory class I ≥100% predicted .37 mmHg
VE/VCO2 slope ,30.0
Ventilatory class II 75–99% predicted 36–30 mmHg
VE/VCO2 slope 30.0–35.9
Ventilatory class III 50–75% predicted 29–20 mmHg
VE/VCO2 slope 36.0–44.9
Ventilatory class IV ,50% predicted ,20 mmHg
VE/VCO2 slope ≥45.0
Standard ET variables
Haemodynamics ECG
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST segment changes during ET and/
or in recovery
Flat systolic BP response during ET Altered rhythm, ectopic foci, and or ST segment changes during ET and/or in
recovery: did not lead to test termination
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment changes during ET and/or in
recovery: led to test termination
Interpretation
† Progressively higher VE/VCO2 slope and lower per cent-predicted peak VO2 and peak PETCO2 indicative of greater HCM severity.
– CPX variables progressing from yellow to orange to red increase the likelihood of increased pulmonary pressure.
† Haemodynamic and ECG responses in yellow and red indicative of increasing risk for sudden cardiac death.
VE/VCO2, minute ventilation/CO2 production; VO2, O2 consumption; PETCO2 apex, partial pressure of end-tidal CO2; BP, blood pressure; CPX, cardiopulmonary exercise test;
ECG, electrocardiogram; ET, exercise test; HCM, hypertrophic cardiomyopathy; VT, ventilatory threshold.
aPeak VO2 valid if peak respiratory exchange ratio is at least 1.00 or test terminated secondary to abnormal haemodynamic or ECG exercise response. Per cent-predicted values
derived from formulas proposed by Wasserman.
bPETCO2 apex is achieved at submaximal levels during a progressive exercise test; typically immediately proceeds VT.
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Appendix 4: Diagnostic stratification for patients with unexplained exertional dyspnoea
Primary CPX variables
VE/VCO2 slope Percent-predicted peak VO2
a PETCO2 VE/MVV
b
Ventilatory class I ≥100% predicted Resting PETCO2 36–42 mmHg .0.80
VE/VCO2 slope ,30.0
Ventilatory class II 75–99% predicted 3–8 mmHg increase during ET
VE/VCO2 slope 30.0–35.9
Ventilatory class III 50–75% predicted Resting PETCO2 ,36 mmHg
,3 mmHg increase during ET
≤0.80
VE/VCO2 slope 36.0–44.9
Ventilatory class IV ,50% predicted
VE/VCO2 slope ≥45.0
Primary PFT variables: FEV1 and PEF
c
No change from pre- to post-CPX ≥15% reduction from pre- to post-CPX
Standard ET variables
Haemodynamics ECG Pulse oximetry
Rise in systolic BP during ET: 10 mmHg/3.5 mL
O2†kg21†min21 increase in VO2
No sustained arrhythmias, ectopic foci, and/or ST segment
changes during ET and/or in recovery
No change in SpO2
from baseline
Flat response or drop in systolic BP during ET Or Altered rhythm, ectopic foci, and or ST segment changes during
ET and/or in recovery: did not lead to test termination
.5% decrease in SpO2
from baseline
Excessive rise in systolic BP during exercise: ≥20 mmHg/
3.5 mL O2†kg21†min21 increase in VO2
Altered rhythm, ectopic foci, and or ST segment changes during
ET and/or in recovery: led to test termination
Interpretation
† Progression of per cent predicted peak VO2 from green to red reflects degree of functional impairment irrespective of mechanism.
† As VE/VCO2 slope progresses from yellow to orange to red and PETCO2 progresses to red, consider exertion-induced increase in pulmonary pressure as
a mechanism.
† Pulse oximetry progression to red indicative of ventilation-perfusion mismatch.
† VE/MVV, FEV1, and PEF in red indicative of pulmonary mechanism; worsening FEV1 and PEF response through first several minutes of recovery
suggestive of EIB; FEV1 response in the red, irrespective of PEF response, also suggestive of EIB.
† Haemodynamic and/or ECG response in red indicative of CV mechanism.
VE/VCO2, minute ventilation/CO2 production; VO2, O2 consumption; PETCO2, partial pressure of end-tidal CO2; VE/MVV, minute ventilation at peak exercise/maximal voluntary
ventilation (maximal voluntary ventilation should be directly measured prior to ET); PFT, pulmonary function test; FEV1, forced expiratory volume in one second; PEF, peak
expiratory flow; BP, blood pressure; CPX, cardiopulmonary exercise test; CV, cardiovascular; ECG, electrocardiogram; ET, exercise test; RER, respiratory exchange ratio; SpO2,
saturation of peripheral O2; EIB, exercise induced bronchospasm.
aPeak VO2 valid if peak RER is at least 1.00 or test terminated secondary to abnormal haemodynamic or ECG exercise response. Percent-predicted values derived from formulas
proposed by Wasserman.
bMVV should be directly measured prior to CPX; the majority of CPX systems allow for MVV measurement.
cFollowing CPX, measurement of FEV1 and PEF should be conducted at 1, 3, 5, 7, 10, 15, and 20 min.
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Appendix 5: Prognostic and diagnostic stratification for patients with suspected or confirmed PAH/secondary PH
Primary CPX variables
VE/VCO2 slope Peak VO2
a PETCO2 apex during exercise
b
Ventilatory class I Weber class A .37 mmHg
VE/VCO2 slope ,30.0 Peak VO2 . 20.0 mL O2†kg21†min21
Ventilatory class II Weber class B 36–30 mmHg
VE/VCO2 slope 30.0–35.9 Peak VO2 ¼ 16.0–20.0 mL O2†kg21†min21
Ventilatory class III Weber class C 29–20 mmHg
VE/VCO2 slope 36.0–44.9 Peak VO2 ¼ 10.0–15.9 mL O2†kg21†min21
Ventilatory class IV Weber class D ,20 mmHg
VE/VCO2 slope ≥45.0 Peak VO2 ,10.0 mL O2†kg21†min21
Standard ET variables
Haemodynamics ECG Pulse oximetry
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST
segment changes during ET and/or in recovery
No change in SpO2 from baseline
Flat systolic BP response during ET Altered rhythm, ectopic foci, and or ST segment
changes during ET and/or in recovery: did not lead
to test termination
.5% decrease in SpO2 from baseline
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment
changes during ET and/or in recovery: led to test
termination
Interpretation
† All variables in green: indicative of good prognosis.
– Maintain medical management and retest in 4 years.
† Greater number of CPX and standard ET variables in red/yellow/orange indicative of progressively worse prognosis.
– All CPX variables in red: risk for major adverse event extremely high in next 1–4 years.
† Greater number of CPX and standard ET variables in red/yellow/orange indicative of increasing severity of pulmonary vasculopathy.
– All CPX variables in red: expect significantly increased pulmonary arterial pressure.
† Greater number of CPX and standard ET variables in red/yellow/orange warrants strong consideration of more aggressive medical management.
VE/VCO2, minute ventilation/CO2 production; VO2, O2 consumption, PETCO2, partial pressure of end-tidal CO2; BP, blood pressure; CPX, cardiopulmonary exercise test; ECG,
electrocardiogram; ET, exercise test; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RER, respiratory exchange ratio; SpO2, saturation of peripheral O2; VT,
ventilatory threshold.
aPeak VO2 valid if peak RER is at least 1.00 or test terminated secondary to abnormal haemodynamic or ECG exercise response.
bPETCO2 apex achieved at submaximal levels; typically immediately proceeds VT.
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Appendix 6: Prognostic and diagnostic stratification for patients with COPD or ILD
VE/VCO2 slope Peak VO2
a PETCO2
Ventilatory class I Weber class A Resting PETCO2 ≥33.0 mmHg
VE/VCO2 slope ,30.0 Peak VO2 .20.0 mL O2†kg21†min21
Ventilatory class II Weber class B 3–8 mmHg increase during ET
VE/VCO2 slope 30.0–35.9 Peak VO2 ¼ 16.0–20.0 mL O2†kg21†min21
Ventilatory class III Weber class C Resting PETCO2 ,33.0 mmHg
VE/VCO2 slope 36.0–44.9 Peak VO2 ¼ 10.0–15.9 mL O2†kg21†min21
Ventilatory class IV Weber class D 3–8 mmHg increase during ET
VE/VCO2 slope ≥45.0 Peak VO2 ,10.0 mL O2†kg21†min21
Standard ET variables
Haemodynamics ECG HRR Pulse oximetry
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST
segment changes during ET and/or in recovery
.12 beats at 1 min
recovery
No change in SpO2 from
baseline
Flat systolic BP response
during ET
Altered rhythm, ectopic foci, and or ST segment
changes during ET and/or in recovery: did not lead to
test termination
≤12 beats at 1 min
recovery
.5% decrease in SpO2 from
baseline
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment
changes during ET and/or in recovery: led to test
termination
Interpretation
† All variables in green: excellent prognosis in next 1–4 years.
– Maintain medical management and retest in 4 years.
† Greater number of CPX and standard exercise test variables in red/yellow/orange indicative of progressively worse prognosis.
– All CPX variables in red: risk for major adverse event extremely high in next 1–4
† Greater number of CPX and standard ET variables in red/yellow/orange indicative of increasing interstitial lung disease severity.
– As VE/VCO2 slope and PETCO2 progress to red, likelihood of secondary PH increases.
† Greater number of CPX and standard ET variables in red/yellow/orange warrants strong consideration of more aggressive medical management and
surgical options.
VE/VCO2, minute ventilation/CO2 production; VO2, oxygen Consumption; PETCO2: partial pressure of end-tidal CO2; BP, blood pressure; COPD, chronic obstructive pulmonary
disease; CPX, cardiopulmonary exercise test; ECG, electrocardiogram; ET, exercise test; HRR, heart rate recovery; ILD, interstitial lung disease; PH, pulmonary hypertension; RER,
respiratory exchange ratio; SpO2, saturation of peripheral O2.
aPeak VO2 valid if peak RER is at least 1.00 or test terminated secondary to abnormal haemodynamic or ECG exercise response.
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Appendix 7: Diagnostic stratification for patients with suspected myocardial ischaemia
Primary CPX variables
O2 pulse trajectory
b Per cent-predicted peak VO2
a DVO2/DW trajectory
b
Continual rise throughout ET with
possible plateau approaching
maximal exertion
≥100% predicted Continual rise throughout ET
Early and sustained plateau 75–99% predicted Early and sustained plateau
50–75% predicted
Early plateau then decline ,50% predicted Early plateau then decline
Standard exercise test variables
Haemodynamics ECG
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST segment changes
during ET and/or in recovery
Flat systolic BP response during ET Altered rhythm, ectopic foci, and or ST segment changes during ET
and/or in recovery: did not lead to test termination
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment changes during ET
and/or in recovery: led to test termination
Patient reason for test termination
Lower extremity muscle fatigue Angina Dyspnoea
Interpretation
† Progression of per cent-predicted peak VO2 from green to red indicative of progressively higher level of ischaemia and functional decline.
† O2 pulse and DVO2/DW trajectory progressing to red indicative of myocardial ischaemia in appropriately screened patients (i.e. baseline signs/
symptoms/risk factors suggesting increased coronary artery disease risk).
† Haemodynamic and ECG responses in yellow and red indicative of abnormal exercise response and further support myocardial ischemia in
appropriately screened patients (i.e. baseline signs/symptoms/risk factors suggesting increased CHD risk).
O2 pulse, oxygen pulse; VO2, oxygen consumption; DVO2/DW, change in oxygen consumption/change in Watts; BP, blood pressure; COPD, chronic obstructive pulmonary disease;
CPX, cardiopulmonary exercise test; ECG, electrocardiogram; ET, exercise test; ILD, interstitial lung disease; PH, pulmonary hypertension; RER, respiratory exchange ratio.
aPer cent-predicted peak VO2 valid if peak RER is at least 1.00 or test terminated secondary to abnormal hemodynamic or ECG exercise response. Per cent-predicted values
derived from formulas proposed by Wasserman
bRequires O2 pulse and DVO2/DW plot from initiation to end of exercise test. If these variables required for assessment, electronically braked cycle ergometer should be used for
testing.
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Appendix 8: Diagnostic stratification for patients with suspected mitochondrial myopathy
Primary CPX variables
DQ/DVO2 Per cent-predicted peak VO2
a Peak VE/VO2
≈5
≥100% predicted ≈40
75–99% predicted 50 ¼ upper limit of normal
≥7
50–75% predicted
.50
,50% predicted
Standard ET variables
Haemodynamics ECG
Rise in systolic BP during ET No sustained arrhythmias, ectopic foci, and/or ST segment changes during
ET and/or in recovery
Flat systolic BP response during ET Altered rhythm, ectopic foci, and or ST segment changes during ET and/or
in recovery: did not lead to test termination
Drop in systolic BP during ET Altered rhythm, ectopic foci, and or ST segment changes during ET and/or
in recovery: led to test termination
Interpretation
† Progression of per cent-predicted peak VO2 from green to red indicative of progressively higher level of mitochondrial dysfunction.
† DQ/DVO2 and peak VE/VO2 in red indicative of mitochondrial myopathy; consider muscle biopsy to obtain definitive diagnosis.
† Although not diagnostic for mitochondrial myopathy, haemodynamic and ECG responses in yellow and red universally indicative of abnormal ET
response.
DQ/DVO2, change in cardiac output/change in O2 consumption; measurement requires additional equipment of assess Q response to ET through non-invasive rebreathing
technique; VO2, O2 consumption; VE/VO2, minute ventilation/O2 consumption; BP, blood pressure; CPX, cardiopulmonary exercise test; ECG, electrocardiogram; ET, exercise test;
RER, respiratory exchange ratio.
aPer cent-predicted peak VO2 valid if peak RER is at least 1.00 or ET terminated secondary to abnormal haemodynamic or ECG exercise response. Per cent-predicted values
derived from formulas proposed by Wasserman.
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